Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 1-2, 2006, Pages 159-169

  Safer, Daniel J ^a,c   Zito, Julie Magno ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; AGITATION; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DROWSINESS; HUMAN; HYPERACTIVITY; HYPERKINESIA; INSOMNIA; NAUSEA; PRESCHOOL CHILD; RESTLESSNESS; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; VOMITING;

ADOLESCENT; AGE FACTORS; CHILD; CONTROLLED CLINICAL TRIALS; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33645826535     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.159     Document Type: Article

References (66)

1. Alderman J, Wolkow R, Chung M, Johnston HE: Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 37:386-394, 1998.
2. Apter A, Ratzoni G, King RA, Weizman A, Jancu I, Binder M, Riddle MA: Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 33:342-348, 1994.
3. Awad GA: The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders. Can J Psychiat 41:361-366, 1996.
4. Beasley CM, Koke SC, Nilsson ME, Gonzales JS: Adverse events and treatment discontinuation in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clin Ther 22:1319-1330, 2000.
5. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty, M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589-594, 2005.
6. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415-423, 2003.
7. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M: Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:993-999, 1994.
8. Braconnier A LeCoent R, Cohen D: Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 42:22-29, 2003.
9. Brambilla P, Cipriani A, Hotopf M, Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic, and newer antidepressants: A meta-analysis of clinical trial data. Pharmacopsychiatry 38:68-77, 2005.
10. Brent RL, Tanski S, Weitzman M: A pediatric perspective on the unique vulnerability and resilience of the embryo and the child to environmental toxicants: The importance of vigorous research concerning age and agent. Pediatrics 113(Suppl):935-944, 2004.
11. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW: Discontinuing or switching selective serotonin reuptake inhibitors. Ann Pharmacotherapy 36:578-584, 2002.
12. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single-isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336, 2002.
13. Cohn JB, Wilcox CS: Paroxetine in major depression: A double-blind trial with imipramine and placebo. J Clin Psychiatry 53(Suppl):52-56, 1992.
14. Cook EH, Rowlett R, Jaselskis C, Leventhal BL: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Amer Acad Child Adolesc Psychiatry 31:739-745, 1992.
15. Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, Messig M: Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 40:1175-1181, 2001.
16. CSM Committee on the Safety of Medicines: Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. December 2004. Online document at: medicines.mhra.gov.uk/ ourwork/monitorsafe qualmed/safetymessages/ssrifinal.pdf
17. Dummit ES, Klein RG, Tancer NK, Asche B, Martin J: Fluoxetine treatment of children with selective mutism: An open trial. J Amer Acad Child Adolesc Psychiatry 35:615-621, 1996.
18. Edwards JG, Anderson I: Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533, 1999.
19. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215, 2002.
20. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997.
21. European Medicines Agency. European Medicines Agency finalizes review of antidepressants in children and adolescents. [Doc. Ref. EMEA/CHMP/128918/2005 corr.] London, April 25, 2005.
22. Feighner JP, Overo K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate to severe depression. J Clin Psychiatry 60:824-830, 1999.
23. Findling RL, Fong R, Carpenter DJ, Nucci G: Multiple-dose pharmacokinetics of paroxetine in pediatric versus adult subjects. Poster presented at the annual meeting of the New Clinical Drug Evaluation Unit, June 8, 2005, Boca Raton, FL.
24. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky L, Waldorf B, Blumer JL: Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 38:952-959, 1999.
25. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE: Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Amer Acad Child Adolesc Psychiatry 34:36-44, 1995.
26. Geller DA, Hoog SI, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled, clinical trial. J Am Acad Child Adolesc Psychiatry 40:773-779, 2001.
27. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43:1387-1396, 2004.
28. Greenhill LL, Vitiello B, Fisher P, Levine J. Davies M, Abikoff H, Chrisman AK, Chuang S, Findling RI, March J, Scahill L, Walkup J, Riddle MA: Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacolgy. J Am Acad Child Adolesc Psychiatry 43:1488-1496, 2004.
29. Hammad T: Results of the analysis of suicidality in pediatric trials of newer antidepressants. Presented at the joint meeting of the CDER psychopharmacologic drug advisory committee and the FDA pediatric advisory committee. September 13, 2004. Online document at: www.fda.gov/ohrms/dockets/ac/ 04/briefing/20044065b1.htm/ Accessed June 2005.
30. Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001.
31. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N: Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse events. J Child Adolesc Psychopharmacol 2:259-265, 1992.
32. Keller MB: Citalopram therapy for depression: A review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61:896-908, 2000.
33. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ: Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772, 2001.
34. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L: Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186, 1991.
35. Kremer CM, Klee BJ, Clary CM, March JS: Safety of sertraline in childhood depression and obsessive compulsive disorder. Poster presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry. Washington (DC), October 22, 2004.
36. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou X, Hays R, Weinberger M: Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. JAMA 286:2947-2955, 2001.
37. Lee M: Nausea and vomiting. In: Gastrointestinal and Liver Disease, 7th ed. Edited by Feldman M, Friedman LS, Sleisenger MH. Philadelphia, Saunders, 2002, pp 119-130.
38. Leslie LK, Newman TB, Chesney PJ, Perrin JM: The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 116:195-204, 2005.
39. Liebowitz MR, Stein MB, Tacer M, Carpenter D, Oakes R, Pitts CD: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66-74, 2002b.
40. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO: Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41:1431-1438, 2002a.
41. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cultler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD: Sertraline in children and adolescents with obsessive-compulsive disorder. JAMA 280:1752-1756, 1998.
42. Martin A, Koenig K, Anderson GM, Scahill L: Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Autism Dev Disord 33:77-85, 2003.
43. Masi G, Toni C, Mucci M, Millepiedi S, Mata B, Perugi G: Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 11:151-157, 2001.
44. McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K: An open study of the effect of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 6:41-51, 1996.
45. Mendels J: Clinical experience with serotonin reuptake-ihhibiting antidepressants. J Clin Psychiatry 48(3)(Suppl):26-30, 1987.
46. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP: Safety reporting in randomized trials in mental health interventions. Am J Psychiatry 161:1692-1697, 2004.
47. Pediatric OCD Treatment Study: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder. JAMA 292:1969-1976, 2004.
48. Raches D, Pravdova I, DeMaso DR, Beardslee WR, Heydrich JG: Sertraline treatment for young children: Systematic review of medical records. Poster presented at the New Clinical Drug Evaluation Unit annual meeting, June 11, 2002, Boca Raton, FL.
49. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51(Suppl B):18-27, 1990.
50. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL: Fluoxetine treatment of children and adolescents with Tourette's and obsessive-compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48, 1990.
51. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JI, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT: Fluoxetine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222-229, 2001.
52. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adoles Psychiatry 31:1062-1069, 1992.
53. Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158:2008-2014, 2001.
54. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004.
55. Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, Leckman JF: Fluoxetine has no marked effect on tic symptoms in patients with Tourette syndrome: A double-blind, placebo-controlled study. J Child Adolesc Psychopharmacol 7:75-85, 1997.
56. Simeon JG, Dinicola VF, Ferguson HB, Copping W: Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 14:791-795, 1990.
57. Soldin SJ, Steele BW: Minireview: Therapeutic drug monitoring in pediatrics. Clin Biochem 33:333-335, 2000.
58. Tierney E, Joshi PT, Llinas JF, Rosennberg LA, Riddle MA: Sertraline for major depression in children and adolescents: Preliminary clinical experience. J Child Adolesc Psychopharmacol 5:13-27, 1995.
59. Treatment for Adolescents with Depression Study (TADS) Team: Fluoxetine, congnitive-behavioral therapy, and their combination for adolescents with depression. JAMA 292:807-820, 2004.
60. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA 290:1033-1041, 2003.
61. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153-1162, 2004b.
62. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083, 2004a.
63. Wagner KD, Wetherhold E, Carpenter DJ, Krulewicz S, Bailey A: Safety and tolerability of paroxetine in children and adolescents: Pooled results from four multicenter, placebo-controlled trials. Presented at the New Clinical Drug Evaluation Unit annual meeting, June 11, 2002, Boca Raton, FL.
64. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 362:1341-1345, 2004.
65. Wilens TE, Biederman J, Kwon A, Chase R, Greenberg L, Mick E, Spencer TJ: A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 13:143-152, 2003.
66. Wilens TE, Cohen L, Biederman J, Abrams A, Neff D, Faird N, Sinha V: Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 22:568-575, 2002.